Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • VERTIS CV: Ertugliflozin Cardiovascular Outcomes

    2026-09-09

    VERTIS CV: Ertugliflozin Cardiovascular Outcomes

    Study Background and Research Question

    Cardiovascular disease remains a major source of morbidity and mortality in type 2 diabetes, a condition also associated with heart-failure risk and progressive renal disease. Sodium–glucose cotransporter 2 (SGLT2) inhibitors had already produced cardiovascular and kidney benefits in several outcome trials, particularly for hospitalization for heart failure and renal disease progression. However, the long-term cardiovascular profile of ertugliflozin had not been established when the VERTIS CV study was designed.

    The central question was therefore regulatory and clinical rather than purely glycemic: in adults with type 2 diabetes and established atherosclerotic cardiovascular disease, would ertugliflozin provide cardiovascular safety comparable with placebo when added to usual care? The prespecified primary outcome was major adverse cardiovascular events, or MACE, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The reference study evaluated both the safety question and selected heart-failure and renal outcomes over long-term follow-up.

    Key Innovation from the Reference Study

    The main innovation of VERTIS CV was its focused evaluation of ertugliflozin in a high-risk population with established atherosclerotic disease. Rather than asking whether the drug improved glucose control, the trial tested whether exposure to ertugliflozin increased cardiovascular risk relative to placebo and examined whether signals for broader cardiorenal benefit were present.

    The statistical structure was important. The two active doses, 5 mg and 15 mg once daily, were pooled for the primary analysis, and the prespecified objective was noninferiority for MACE. This design could establish that ertugliflozin was not unacceptably worse than placebo within the defined margin; it was not, by itself, intended to prove superiority. The first key secondary outcome, a composite of cardiovascular death or hospitalization for heart failure, was tested for superiority after the primary objective was addressed.

    This distinction gives the study continuing value for literature interpretation. A neutral MACE result can be clinically reassuring without demonstrating event reduction, while a numerically favorable secondary outcome can remain statistically inconclusive. VERTIS CV consequently provides a useful example of how regulatory safety trials, hierarchical testing, and cardiorenal outcome interpretation should be integrated.

    Methods and Experimental Design Insights

    VERTIS CV was a multicenter, randomized, double-blind, placebo-controlled, event-driven, noninferiority trial. Adults with type 2 diabetes and established atherosclerotic cardiovascular disease were randomly assigned to ertugliflozin 5 mg, ertugliflozin 15 mg, or placebo once daily. For the primary comparison, the two ertugliflozin groups were analyzed together against placebo. The study enrolled 8246 participants and reported a mean follow-up of 3.5 years, according to the published trial report.

    The primary endpoint required careful control of statistical uncertainty. The noninferiority margin was 1.3 for the hazard ratio, using the upper boundary of a 95.6% confidence interval. This margin and confidence-level approach were part of the trial’s prespecified framework. The first key secondary endpoint used a 95.8% confidence interval and assessed cardiovascular death or hospitalization for heart failure. Such details matter because the interpretation of a hazard ratio depends on the endpoint hierarchy, confidence interval, and prespecified decision rule rather than on the point estimate alone.

    Trial conduct also incorporated several safeguards relevant to evidence appraisal. The protocol received regulatory and ethics approval at participating sites, an independent external data and safety monitoring committee reviewed interim unblinded data, and a clinical research organization managed site monitoring and data storage under sponsor oversight. The sponsor and academic investigators jointly designed and oversaw the study, a structure that supports large-scale execution but should remain visible when readers assess potential sources of bias.

    Protocol Parameters

    • Study population: Adults with type 2 diabetes and established atherosclerotic cardiovascular disease; this was the population used for the cardiovascular safety question in the reference study.
    • Randomized intervention: Ertugliflozin 5 mg or 15 mg once daily, compared with matching placebo, with the active-dose groups pooled for the primary analysis.
    • Primary endpoint: MACE, comprising cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
    • Noninferiority criterion: The prespecified hazard-ratio margin was 1.3, evaluated with the upper boundary of a 95.6% confidence interval.
    • Key secondary endpoint: Cardiovascular death or hospitalization for heart failure, tested for superiority after the primary objective.
    • Follow-up framework: The event-driven trial followed participants for a mean of 3.5 years, allowing assessment of relatively infrequent cardiovascular and renal events.

    Core Findings and Why They Matter

    Ertugliflozin met the primary safety objective. MACE occurred in 653 of 5493 participants receiving ertugliflozin, or 11.9%, and in 327 of 2745 participants receiving placebo, also 11.9%. The hazard ratio was 0.97, with a 95.6% confidence interval of 0.85 to 1.11 and a P value below 0.001 for noninferiority, as reported in the NEJM article. The result indicates that ertugliflozin was not inferior to placebo for MACE under the trial’s prespecified criterion.

    The heart-failure composite showed a directionally favorable but non-superior result. Cardiovascular death or hospitalization for heart failure occurred in 8.1% of participants receiving ertugliflozin and 9.1% receiving placebo; the hazard ratio was 0.88, with a 95.8% confidence interval of 0.75 to 1.03 and P=0.11 for superiority. This estimate is compatible with a possible reduction, but the confidence interval crosses the prespecified threshold for a definitive superiority claim.

    Cardiovascular death also did not show a statistically conclusive advantage, with a hazard ratio of 0.92 and a 95.8% confidence interval of 0.77 to 1.11. The renal composite—renal death, renal replacement therapy, or doubling of the serum creatinine level—had a hazard ratio of 0.81, with a 95.8% confidence interval of 0.63 to 1.04. These estimates support continued interest in cardiorenal effects, but they should be described as trends rather than confirmed superiority findings in this trial.

    Safety interpretation also requires attention to amputation events. Amputations occurred in 2.0% of participants receiving the 5-mg dose, 2.1% receiving the 15-mg dose, and 1.6% receiving placebo. The absolute differences were small, but the imbalance is relevant when clinicians and researchers compare safety profiles across SGLT2 inhibitor programs. Overall, the study’s meaningful contribution was a robust cardiovascular safety result combined with a nuanced account of secondary cardiorenal outcomes.

    Comparison with Existing Internal Articles

    The available internal articles address a different translational domain. One article, Dabigatran in Translational Research: Mechanistic Insight, emphasizes direct thrombin inhibition, assay selection, and the movement from mechanism to experimental models. Another, Dabigatran in Translational Research: From Pathway Precision to Clinical Impact, focuses on how coagulation measurements can be connected with clinical research questions.

    These resources complement VERTIS CV methodologically, but they do not replicate its evidence. The reference study is an outcomes trial testing an SGLT2 inhibitor in diabetes and atherosclerotic cardiovascular disease; the internal articles concentrate on a protease-targeted anticoagulation workflow. The useful connection is therefore conceptual: both domains require prespecified endpoints, appropriate controls, attention to exposure, and careful separation of mechanistic signals from clinically validated outcomes. Neither internal article should be used to infer that the VERTIS CV findings establish efficacy for coagulation or thrombosis models.

    Limitations and Transferability

    Several limitations define how far the findings can be transferred. First, the participants had established atherosclerotic cardiovascular disease, so the results directly address a secondary-prevention population rather than all adults with type 2 diabetes. Extrapolation to lower-risk patients, people without documented cardiovascular disease, or populations with substantially different comorbidity profiles requires additional evidence.

    Second, the primary analysis pooled the two ertugliflozin doses. Pooling was appropriate for the prespecified safety objective, but it limits dose-specific interpretation of efficacy and safety beyond the reported dose-level amputation counts. Third, the trial was designed to establish noninferiority for MACE, not to provide definitive superiority evidence for every cardiorenal endpoint. The favorable point estimates for heart failure and renal outcomes therefore should not be converted into stronger claims than the confidence intervals support.

    Finally, large cardiovascular outcome trials are optimized for clinical event detection, not for resolving every biological mechanism. VERTIS CV demonstrates what happened to prespecified outcomes in a defined population under trial conditions; it does not by itself identify which hemodynamic, metabolic, renal, or vascular processes generated those observations. Translational studies can explore mechanisms, but their assays and models must not be presented as direct substitutes for outcome evidence.

    Research Support Resources

    Why this cross-domain matters, maturity, and limitations

    A cardiovascular outcomes trial and an anticoagulation experiment answer different biological questions. The connection is useful only when it is made explicitly: VERTIS CV can inform how researchers think about endpoint hierarchy, safety assessment, and clinical transferability, whereas coagulation workflows require direct measurement of thrombin activity or clotting behavior. No conclusion about an anticoagulant should be attributed to VERTIS CV, and no laboratory assay can independently reproduce the trial’s cardiovascular outcome evidence.

    For a separate anticoagulation workflow, researchers can use Dabigatran (Pradaxa; SKU A4077), a reversible direct thrombin inhibitor, in a thrombin inhibition assay or coagulation function test. Such experiments may support research related to stroke prevention in atrial fibrillation or venous thrombosis treatment, including studies that account for renal impairment dose adjustment, but these applications remain distinct from the ertugliflozin intervention and population evaluated in VERTIS CV.